Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
Autor: | Hoppe, Bernd, Koch, Annelize, Cochat, Pierre, Garrelfs, Sander F., Baum, Michelle A., Groothoff, Jaap W., Lipkin, Graham, Coenen, Martin, Schalk, Gesa, Amrite, Aniruddha, McDougall, David, Barrios, Kelly, Langman, Craig B. |
---|---|
Zdroj: | In Kidney International March 2022 101(3):626-634 |
Databáze: | ScienceDirect |
Externí odkaz: |